Contraindicated (one)nirmatrelvir/ritonavir will increase the degree or impact of triazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolism.Keep away from concomitant use of tucatinib with CYP3A substrates, where by negligible focus modifications may produce critical or lifetime-threatening toxicities. If unavoidable, lessen CYP3A substr